Session

Urothelial tumours: New systemic treatment options and multidisciplinary management

Poster Session 90

  • Location:
    Room Vienna (Hall B2, level 0)
  • Chairs:
     I. Duran, Seville (ES)
     B.R. Konety, Minneapolis (US)
     C.N. Sternberg, Rome (IT)
  • Aims and objectives of this session

    This session will focus on new systemic treatment options with targeted agent and immunotherapy and the importance of multidisciplinary management.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 1142
Efficacy of atezolizumab (MPDL3280A) in platinum-treated metastatic urothelial carcinoma (mUC): Update from the IMvigor 210 phase II clinical trial

By: Van Der Heijden M.1, Retz M.2, Perez-Gracia J.L.3, Necchi A.4, Powles T.5, Sridhar S.S.6, Neigisch G.7, Theodore C.8, Bracarda S.9, Duran I.10, Carles J.11, Rosenberg J.12, Dreicer R.13, Grande E.14, Cui N.15, Mariathasan S.15, Thåström A.15, Loriot Y.16

Institutes: 1The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, 2Technische Universität München, Dept. of Urology, Munich, Germany, 33Clinica Universidad De Navarra, Dept. of Urology, Pamplona, Spain, 4Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 5Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, 6University Health Network, Princess Margaret Cancer Center, Toronto, Canada, 7Universitätsklinikum Düsseldorf, Dept. of Urology, Düsseldorf, Germany, 8Hopital Foch, Dept. of Oncology, Suresnes, France, 9Ospedale San Donato, Istituto Toscano Tumori, Arezzo, Italy, 10Hospital Universitario Virgen Del Rocio, Dept. of Urology, Seville, Spain, 11Vall D’Hebron University Hospital, Vall D’Hebron Institute of Oncology, Barcelona, Spain, 12Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 13University of Virginia, Dept. of Hematology/Oncology, Charlottesville, United States of America, 14Hospital Universitario Ramón Y Cajal, Dept. of Urology, Madrid, Spain, 15Genentech, Inc., Dept. of Oncology, South San Francisco, United States of America, 16Gustave Roussy, Dept. of Oncology, Villejuif, France

1143
A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010)

By: Castellano D.1, Albers P.2, Gschwend J.E.3, Culine S.4, Bullmunt J.5, Hussain M.6, Shen X.7, Nelson B.8, Powles T.9

Institutes: 1Hospital Universitario 12 De Octubre, Dept. of Oncology, Madrid, Spain, 2University of Düsseldorf, Dept. of Urology, Dusseldorf, Germany, 3Technical University of Munich, Dept. of Urology, Munich, Germany, 4Hôpital Saint-Louis, Dept. of Urology, Paris, France, 5Harvard Medical School, Bladder Cancer Center, Boston, United States of America, 6University of Michigan, Dept. of Urology, Ann Arbor, United States of America, 7Genentech, Inc., Dept of Oncology, South San Francisco, United States of America, 8Genentech, Inc., Dept. of Oncology, South San Francisco, United States of America, 9Queen Mary University of London, Barts Cancer Institute, London, United Kingdom

* 1144
A phase 2 study of the Aurora Kinase-A (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pre-treated urothelial cancer (UC)

By: Necchi A.1, Raggi D.1, Lo Vullo S.2, Mariani L.2, Giannatempo P.1, Calareso G.3, Togliardi E.4, Nicolai N.5, Perrone F.6, Pelosi G.6, Salvioni R.5, De Braud F.1

Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS – Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 6Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy

1146
FDG PET/CT imaging as a diagnostic tool for response evaluation in bladder cancer patients following neoadjuvant chemotherapy

By: Fransen Van De Putte E.1, Vegt E.2, Mertens L.1, Fioole-Bruining A.3, Van Der Heijden M.4, Horenblas S.1, Van Rhijn B.1

Institutes: 1The Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, 2The Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, 3The Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Radiology, Amsterdam, The Netherlands, 4The Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Medical Oncology, Amsterdam, The Netherlands

1147
Neutrophil-to-lymphocyte ratio as a predictor of response to neo-adjuvant chemotherapy in muscle-invasive bladder cancer

By: Van Kessel K.1, De Haan L.2, Fransen Van De Putten E.3, Van Rhijn B.3, De Wit R.4, Van Der Heijden M.5, Zwarthoff E.2, Boormans J.1

Institutes: 1Erasmus MC Cancer Institute, Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus MC Cancer Institute, Erasmus Medical Center, Dept. of Pathology, Rotterdam, The Netherlands, 3Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Surgical Oncology, Division of Urology, Amsterdam, The Netherlands, 4Erasmus MC Cancer Institute, Erasmus Medical Center, Dept. of Medical Oncology, Rotterdam, The Netherlands, 5Netherlands Cancer Institute, Dept. of Medical Oncology, Division of Molecular Carcinogenesis, Amsterdam, The Netherlands

1149
Non-invasive characterization of metastatic urothelial carcinoma by next-generation sequencing of cell free DNA

By: Todenhöfer T.1, Volik S.1, Eigl B.2, North S.3, Brahmbhatt S.1, Haegert A.1, Stenzl A.4, Mischinger J.4, Le Bihan S.1, Wyatt A.1, Collins C.1, Black P.C.1

Institutes: 1University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, 2British Columbia Cancer Agency, Medical Oncology, Vancouver, Canada, 3University of Alberta, Medical Oncology, Edmonton, Canada, 4Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

1150
Adjuvant chemotherapy after radical cystectomy decreases mortality in locally advanced or lymph node positive tumours

By: Fröhner M.1, Koch R.2, Heberling U.1, Novotny V.1, Oehlschlaeger S.1, Wirth M.1

Institutes: 1Technical University Dresden, Dept. of Urology, Dresden, Germany, 2Technical University Dresden, Dept. of Medical Informatics, Dresden, Germany

* 1151
Gemcitabine plus paclitaxel as third‐line chemotherapy: A feasible option for metastatic urothelial carcinoma patients

By: Iida K., Nagai T., Etani T., Naiki T., Ando R., Kawai N., Tozawa K., Yasui T.

Institutes: Nagoya City University, Graduate School Of Medical Sciences, Dept. of Nephro-urology, Nagoya, Japan

1152
Neoadjuvant chemotherapy before radical cystectomy in patients with urothelial carcinoma of the bladder: Current practice among clinicians

By: Martini T.1, Gilfrich C.2, Deuschle F.18, Mayr R.3, Burger M.3, Pycha A.4, Aziz A.5, Gierth M.3, Stief C.G.6, Müller S.C.7, Wagenlehner F.8, Roigas J.9, Hakenberg O.W.10, Roghmann F.11, Nuhn P.18, Wirth M.12, Hadaschik B.13, Grimm M-O.14, Schramek P.15, Haferkamp A.16, Kloss B.17, Colleselli D.17, Herrmann E.19, Fisch M.5, May M.2, Bolenz C.1

Institutes: 1University of Ulm Medical School, Dept. of Urology, Ulm, Germany, 2Urologische Klinik, Klinikum St. Elisabeth Straubing, Dept. of Urology, Straubing, Germany, 3Caritas St. Josef Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, 4General Hospital of Bolzano, Dept. of Urology, Bolzano, Italy, 5University Medical Centre Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 6Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, 7Klinik Und Poliklinik Für Urologie Und Kinderurologie, Dept. of Urology, Bonn, Germany, 8Clinic For Urology, Pediatric Urology and Andrology, Justus-Liebig University,Giessen, Dept. of Urology, Giessen, Germany, 9Vivantes Medical Centre Im Friedrichshain and Am Urban, Berlin, Dept. of Urology, Berlin, Germany, 10University Hospital Rostock, Dept. of Urology, Rostock, Germany, 11Marienhospital Herne, Ruhr-University Bochum, Dept. of Urology, Bochum, Germany, 12University Hospital “Carl Gustav Carus”, Dresden University of Technology, Dept. of Urology, Dresden, Germany, 13University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 14University Hospital of Jena, Dept. of Urology, Jena, Germany, 15Hospital Saint John of God Vienna, Dept. of Urology, Vienna, Austria, 16Goethe-University Frankfurt, Dept. of Urology, Frankfurt, Germany, 17Paracelsus Medical University, Salzburg, Dept. of Urology, Salzburg, Austria, 18Mannheim Medical Center, University of Heidelberg, Dept. of Urology, Mannheim, Germany, 19University of Münster, Münster, Dept. of Urology, Münster, Germany

Summary and context
 I. Duran, Seville (ES)